Medical treatments that target the hormone-producing neurons in the brain, called DMDD, are popular with sufferers of a severe form of anxiety disorder, according to a doctor.
The Drug and Device Administration on Wednesday approved the drug, which can treat people who have the condition known as hyposporia, for the treatment of a subset of the disorder, called DMDD.DMDD is a condition that affects the ability to experience emotions and emotions are caused by the disorder.DMJD affects about 10 percent of adults.
“I am pleased to report the FDA has approved the DMDD medication, which will be administered as an outpatient, to treat individuals who have DMDD and are currently experiencing negative mood or anxiety,” Dr. Eric Lichtman, a clinical psychiatrist at the University of California San Francisco, said in a statement.
Lichtman said the drug is designed to help reduce negative symptoms.
The drug is a generic form of DMDD that can be prescribed for individuals who don’t have symptoms and have not responded to other treatment.
“We know that DMDD affects around 10 percent [of people], and we’re targeting it in that group,” Lichtmen said.DMFD is caused by an abnormal genetic mutation in the gene responsible for making a hormone called somatostatin.
It’s the first time such a drug has been approved for treating DMDD in the United States.”DMFD has a good safety profile, and we are hopeful this approval will lead to a new class of DMFD therapies, which could ultimately be more effective,” Lichman said.
He said the DMFD drug was first approved for treatment in the UK in 2011, and he expects it will be approved in the US in the coming months.
The DMDD drug is not available in the U.S., but it is approved in Europe.
The Drug and Medical Devices Administration approved DMDD for the U of T last year.
The FDA said it will begin to roll out DMDD to the U in the next few months.